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A B S T R A C T
Objectives: We critically evaluated the quality of evidence and quality of harm reporting in clinical trials
that evaluated the effectiveness of hydroxychloroquine (HCQ) or chloroquine (CQ) for the treatment of
coronavirus disease 2019 (COVID-19).
Study design and setting: Scientific databases were systematically searched to identify relevant trials of
HCQ/CQ for the treatment of COVID-19 published up to 10 September 2020. The Cochrane risk-of-bias
tools for randomized trials and non-randomized trials of interventions were used to assess risk of bias in
the included studies. A 10-item Consolidated Standards of Reporting Trials (CONSORT) harm extension
was used to assess quality of harm reporting in the included trials.
Results: Sixteen trials, including fourteen randomized trials and two non-randomized trials, met the
inclusion criteria. The results from the included trials were conflicting and lacked effect estimates
adjusted for baseline disease severity or comorbidities in many cases, and most of the trials recruited a
fairly small cohort of patients. None of the clinical trials met the CONSORT criteria in full for reporting
harm data in clinical trials. None of the 16 trials had an overall ‘low’ risk of bias, while four of the trials had
a ‘high’, ‘critical’, or ‘serious’ risk of bias. Biases observed in these trials arise from the randomization
process, potential deviation from intended interventions, outcome measurements, selective reporting,
confounding, participant selection, and/or classification of interventions.
Conclusion: In general, the quality of currently available evidence for the effectiveness of CQ/HCQ in
patients with COVID-19 is suboptimal. The importance of a properly designed and reported clinical trial
cannot be overemphasized amid the COVID-19 pandemic, and its dismissal could lead to poorer clinical
and policy decisions, resulting in wastage of already stretched invaluable health care resources.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.




 Currently, published controlled clinical trials that evaluated the
effectiveness and safety of hydroxychloroquine (HCQ) or
chloroquine (CQ) in the treatment of coronavirus disease 2019
(COVID-19) have not only several methodological limitations but
also the findings were significantly confounded by the lack of
reporting and/or statistical adjustment of baseline disease
severity.
 None of the 16 controlled trials included in this review met the
Consolidated Standards of Reporting Trials (CONSORT) criteria in
full for reporting harm data in clinical trials. Published trials
were associated with a moderate to high risk of bias, which raises
further questions on the validity of the trials’ findings.
 Given the questionable quality of evidence available, it is not
possible to draw a meaningful conclusion on the effectiveness
and the safety of HCQ/CQ for the treatment of patients with
COVID-19.
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 The methodological and reporting quality of trials is of
fundamental importance to inform evidence-based medicine.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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clinical trials of HCQ/CQ to assess their effectiveness in patients
with COVID-19.
What are the implications and what should change now?
 Well-designed, well-conducted, and transparently reported
clinical trials are important for clinicians and public health
organizations to make a careful risk–benefit assessment of
interventions for patients with COVID-19. The need to swiftly
find a cure for a pandemic such as COVID-19 should not be an
excuse to lower the quality threshold for the design and
reporting of clinical trials.
Introduction
Since its outbreak in December 2019, coronavirus disease 2019
(COVID-19), which is caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), has affected more than fourty million
individuals across the world (World Health Organization, 2020;
Dong et al., 2020). The full spectrum of clinical manifestations of
COVID-19 ranges from asymptomatic or mild, self-limiting
respiratory tract illness to severe progressive pneumonia, multi-
organ failure, and death (Huang et al., 2020a). The reported case
fatality rate of COVID-19 is highly variable, ranging from about
0.06% to 19%, depending on countries, settings, and age groups
(Anon, 2020a). The case fatality rate is higher for hospitalized
COVID-19 patients, with population data from the UK suggesting a
case fatality rate of 26% (Docherty et al., 2020).
Many candidate drugs have been proposed for the treatment of
COVID-19, but the antimalarial agents chloroquine (CQ) and
hydroxychloroquine (HCQ) have attracted much attention (Anon,
2020b). In vitro studies have suggested direct antiviral properties
of these antimalarial agents through the inhibition of pH-
dependent steps of viral replication, while other researchers have
suggested anti-inflammatory effects mediated by inhibition of the
production of tumour necrosis factor alpha and interleukin 6, thus
blocking the cascade of events leading to acute respiratory distress
syndrome (Savarino et al., 2003). The use of antimalarials first
attracted media attention in February 2020 after a news briefing by
the Chinese government revealed that, according to several
Chinese studies, CQ and HCQ seemed “to have apparent efficacy
and acceptable safety for the treatment of COVID-19” (Hasan et al.,
2020). A second boost of attention on antimalarials came after the
publication of a non-randomized study—with considerable meth-
odological limitations—claiming that a combination of HCQ and
azithromycin achieved more rapid SARS-CoV-2 clearance in
respiratory secretions of 20 patients (Gautret et al., 2020), which
was followed by the drug combination being touted numerous
times by the president of the United States as a potential cure for
patients with COVID-19 in the media (Anon, 2020c).
Evidence-based medicine is one of the cornerstones of high-
quality clinical care. It has been well established that the best
evidence comes from well-designed and well-conducted random-
ized controlled trials. The promising signals from in vitro studies or
uncontrolled data must be rigorously confirmed or refuted in high-
quality randomized controlled trials. Ideally, efficacy-based trials,
including proof-of-mechanism studies, should precede larger
pragmatic effectiveness trials (Ford and Norrie, 2016). However,
the development of robust evidence through well-designed and
well-conducted trials can be challenging, particularly during a
pandemic (Knottnerus and Tugwell, 2020), and thus there may be a
temptation to lower the ‘quality threshold’ and overlook the
limitations associated with study design either in the wider
interest of public health or to claim a ‘breakthrough’. However,
such temptation must be resisted because falsely adoptingineffective and potentially unsafe interventions on the basis of
studies with methodological flaws may only cause harm without a
noteworthy benefit. This may eventually have a negative impact
not only on the design of other clinical trials but also on the course
to find truly effective and safe interventions.
In addition to robust trial design, transparent and accurate
reporting of trial data is equally important, especially reporting of
harm data related to interventions. Optimal collection and
reporting of adverse events (AEs) during any clinical trial should
not be overlooked in order for clinicians to make a comprehensive
risk–benefit assessment for their patients, who may have other
underlying conditions that contraindicate the use of a particular
drug, either relatively or absolutely. Studies have examined the
methods for AE collection and presentation and highlighted
inadequacies and inconsistencies in AE reporting in various
published clinical trials (Ioannidis and Contopoulos-Ioannidis,
1998; Edwards et al., 1999; Cornelius et al., 2013; Hadi et al., 2017).
In 2004, the Consolidated Standards of Reporting Trials (CONSORT)
Group produced an extension to its guidelines for reporting trial
results to include the reporting of harms, but these guidelines are
poorly implemented in practice (Ioannidis et al., 2004).
The number of clinical trials assessing various treatment
strategies for COVID-19 continues to increase; however, although
some are good, the quality of most of these trials remains
questionable. It is, therefore, more important than ever to critically
assess the quality of emerging evidence from clinical trials amid
the COVID-19 pandemic. This review aims to systematically
summarize and critically evaluate the quality of evidence from
all clinical trials of CQ or HCQ for the treatment of COVID-19 and to
evaluate the quality of AE assessment and reporting in these trials.
Review methods
Search strategy and selection criteria
The Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guideline was followed for the study
design, search protocol, screening, and reporting. Articles were
searched with a predefined search strategy and eligibility criteria.
A systematic search was performed in electronic databases—
PubMed, EMBASE, medRxiv (a preprint repository), Bibliovid,
Google Scholar, and Dimensions—to retrieve eligible articles
published between 1 December 2019 and 10 September 2020.
We also searched for other eligible studies by screening the
reference lists of relevant articles as well as unpublished studies in
the ClinicalTrials.gov database. The search strategy included all
MeSH terms and free keywords found for COVID-19, SARS-CoV-2,
and CQ/HCQ. The following search terms were also used: “anti-
malarial”, “antimalarials”, “chloroquine* OR CQ OR Aralen”,
“hydroxychloroquine OR HCQ OR Plaquenil”, and “COVID-19 OR
2019-nCoV OR SARS-COV-2 OR Wuhan virus OR coronavirus”.
Two authors (SSH and FM) independently searched the electronic
databases and selected the articles against the eligibility criteria.
Discrepancies between them in the selection of articles for inclusion
were resolved by discussion with a third author to achieve a
consensus. The study was included if (1) it was a randomized or non-
randomized controlled trial and (2) it reported the effects of CQ and/
or HCQ compared with placebo and/or active comparator treatment
(s) in COVID-19 patients. Studies were excluded if they were (1)
observational studies, animal studies, reviews, case reports, or in
vitro studies and (2) duplicate publications.
Risk of bias assessment
Two authors (SSH and FM) assessed the risk of bias in the
studies included in the systematic review. Version 2 of the
F. Mazhar, M.A. Hadi, C.S. Kow et al. / International Journal of Infectious Diseases 101 (2020) 107–120 109Cochrane risk-of-bias tool for randomized trials (RoB 2) (Higgins
et al., 2011), which is a standardized method for assessing potential
bias in reports of randomized interventions, was used to assess the
risk of bias in the included randomized trials. RoB 2 is structured
into a fixed set of domains of bias, focusing on different aspects of
trial design, conduct, and reporting. A proposed judgement about
the risk of bias arising from each domain is generated by an
algorithm, where judgement can be ‘low’ or ‘high’ risk of bias or
can express ‘some concerns’. For non-randomized trials, the bias
was assessed by the Risk of Bias in Non-randomized Studies of
Interventions (ROBINS-I) tool (Sterne et al., 2016). Similarly,
ROBINS-I, which is structured into a fixed set of domains of bias,
includes signalling questions that inform the risk of bias judge-
ments, and on the basis of answers to the questions, judgements
for each bias domain, and the overall risk of bias can be classified as
‘low’, ‘moderate’, ‘serious’, or ‘critical’ risk of bias.
Quality of reporting of harm data
For this systematic review, we considered harms to be a
continuum of all adverse treatment effects, including tolerability
issues at the lower end and safety concerns at the upper end, a
definition consistent with the 2004 CONSORT harm recommen-
dations (Ioannidis et al., 2004). Data on harm reporting were
assessed with use of a 10-item checklist, ‘CONSORT Extension for
Harms’ (Ioannidis et al., 2004). The 10-item checklist was adapted
and modified as there are multiple items of interest within a single
CONSORT harm recommendation, and thus scoring the multiple
items within a single recommendation would have been difficult
and misleading. Therefore, where appropriate, we split the single
CONSORT harm extension items into two or three items, resulting
in a 19-item checklist. Each item of the 19-item checklist was
scored individually and weighted with equal importance in line
with CONSORT harm recommendations. Each item carries a score
of 1 if it was adequately reported or 0 if it was inadequately
reported or not reported at all. The total harm reporting score
(THRS) was calculated by summation of all the individual scores,
with maximum and minimum scores of 19 and 0, respectively. AllFigure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA
CQ, chloroquine; HCQ, hydroxychloroquine.included trials were coded by one author (FM) using the
descriptors from the CONSORT Extension for Harms and subse-
quently cross-verified by a second author (SSH).
Data extraction, analysis, and reporting
Extracted data from all included studies were compiled into an
electronic summary table. The following pertinent information
was extracted: all-cause mortality, the requirement for mechani-
cal ventilation, virological clearance, radiological results, admis-
sion to the intensive care unit, confirmation of COVID-19 status,
development of new symptoms, serious AEs, and total AEs.
Further parameters of interest included the number of patients,
number of controls, mean age, sex distribution, baseline disease
severity, treatment options, treatment dosage, and treatment
duration.
We summarized the quantitative findings of individual studies
and used a descriptive approach for reporting of harms. The
percentage of trials fulfilling each CONSORT Extension for Harms
recommendation and the number of recommendations fulfilled by
each trial were tabulated descriptively. In addition, after the
calculation of the THRS for all included trials, we determine the
median THRS along with the interquartile range.
Results
Results of the search
A total of 1320 records were identified from the literature
search. After the initial screening, the full text was retrieved for 74
potentially eligible abstracts. Implementation of the eligibility
criteria resulted in 16 clinical trials being included (Abd-Elsalam
et al., 2020; Borba et al., 2020; Boulware et al., 2020; Cavalcanti
et al., 2020; C. Chen et al., 2020; J. Chen et al., 2020; Z. Chen et al.,
2020; Furtado et al., 2020; Gautret et al., 2020; Horby et al., 2020;
Huang et al., 2020; Mitjà et al., 2020a, 2020b; Skipper et al., 2020;
Tang et al., 2020; Esper et al., 2020). Data were extracted from
these 16 clinical trials (Figure 1).) flow diagram of the study selection process. COVID-19, coronavirus disease 2019;
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Sixteen clinical trials were included in this systematic review
(Abd-Elsalam et al., 2020; Borba et al., 2020; Boulware et al.,
2020; Cavalcanti et al., 2020; C. Chen et al., 2020; J. Chen et al.,
2020; Z. Chen et al., 2020; Furtado et al., 2020; Gautret et al.,
2020; Horby et al., 2020; Huang et al., 2020; Mitjà et al., 2020a,
2020b; Skipper et al., 2020; Tang et al., 2020; Esper et al., 2020):
two non-randomized controlled trials (Gautret et al., 2020; Esper
et al., 2020), two double-blind randomized controlled trials
(Boulware et al., 2020; Skipper et al., 2020), and 12 open-label
randomized controlled trials (Abd-Elsalam et al., 2020; Borba
et al., 2020; Cavalcanti et al., 2020; C. Chen et al., 2020; J. Chen
et al., 2020; Z. Chen et al., 2020; Furtado et al., 2020; Horby et al.,
2020; Huang et al., 2020; Mitjà et al., 2020a, 2020b; Tang et al.,
2020). The sample size in these 16 trials ranged from 22 to 4716
participants. The characteristics of these trials are summarized in
Table 1.
Most trials (n = 9) (Gautret et al. (2020), Chen et al. (2020a),
Chen et al. (2020b), Esper et al. (2020), Borba et al. (2020),
Boulware et al. (2020), Horby et al. (2020), Abd-Elsalam et al.
(2020), and Mitjà et al., 2020) provided no information on baseline
disease severity, although it may not be significant for the trials by
Esper et al. (2020), Boulware et al. (2020) and Mitjà et al., 2020
since they evaluated HCQ as postexposure prophylaxis. Tang et al.
(2020) defined disease severity on the basis of the Chinese
guidelines for the management of COVID-19. Chen et al. (2020c)
categorized patients into different disease severity levels on the
basis of chest radiographic findings. Mitjà et al., 2020 enrolled
patients with mild disease presenting with symptoms including
fever, acute cough, shortness of breath, sudden olfactory or
gustatory loss, or influenza-like illness. Skipper et al. (2020)
evaluated the severity of disease on the basis of a 10-point visual
analogue scale. Furtado et al. (2020) included patients with severe
disease based on the use of oxygen supplementation with a flow
rate of more than 4 L/min, the use of a high-flow nasal cannula, the
use of non-invasive positive-pressure ventilation, and the use of
mechanical ventilation. Although Cavalcanti et al. (2020) specified
that they enrolled participants with mild-to-moderate disease, no
information was given on such a definition or the breakdown of the
proportions of participants with either mild or moderate disease.
Huang et al. (2020b) recruited patients with moderate-to-severe
disease but did not give information on such a definition, although
they did provide the proportions of participants with moderate or
severe disease, respectively. The trials by Tang et al. (2020), Huang
et al. (2020b) and Chen et al. (2020c) were found to have baseline
differences in disease severity between the treatment arm and the
comparator arm. None of the trials statistically adjusted disease
severity at the baseline.
Outcome measures
Four trials (Gautret et al., 2020; Chen et al., 2020a; Tang et al.,
2020; Chen et al., 2020c) of orally administered HCQ used viral
clearance as the outcome measure. With a daily oral dose of 400
mg of HCQ for 5 days, Chen et al. (2020a) reported a negative
conversion rate on day 7 in a pharyngeal swab of 86.7% in the HCQ
group (n = 15), compared with 93.0% for the control group (n = 15).
Tang et al. (2020), who used a loading plus maintenance dose
regimen of HCQ, reported a 28-day negative conversion rate of
85.4% in the HCQ arm (n = 75), compared with 81.3% in the standard
of care arm (n = 75). Chen et al. (2020c) used a loading plus
maintenance dose regimen of HCQ, and reported a 14-day negative
conversion rate of 81.0% for the HCQ group (n = 21) and 75.0% for
the standard of care group (n = 12). Gautret et al. (2020) use a daily
oral dose of 600 mg of HCQ, and reported a higher viral clearancerate of 70% in the HCQ arm (n = 20) compared with 12.5% in the
control arm (n = 16) at 6 days.
Hospital admission as the outcome measure was used in three
trials (Mitjà et al., 2020; Skipper et al., 2020; Esper et al., 2020).
Esper et al. 2020 administered HCQ with azithromycin (HCQ at a
dose of 800 mg on the first day and 400 mg for another 6 days and
azithromycin at a dose of 500 mg once daily for 5 days; n = 412) for
patients with suspected COVID-19, and reported a lower hospitali-
zation rate of 1.9% compared with 5.4% in the control group, who
refused the trial drug (n = 224). Mitjà et al., 2020 in their trial
involving patients with mild symptoms of COVID-19 reported
hospitalization rates of 5.9% in the HCQ arm (800 mg on day 1,
followed by 400 mg once daily for another 6 days; n = 136) and 7.1%
in the control arm (n = 157). Skipper et al. (2020), who enrolled
non-hospitalized adults with suspected or confirmed COVID-19,
reported hospitalization rates of 1.8% for the HCQ group (800 mg
once, followed by 600 mg in 6–8 h, then 600 mg daily for another 4
days; n = 212) and 4.7% for the placebo group (n = 211).
Death as the outcome was reported in four trials (Cavalcanti
et al., 2020; Horby et al., 2020; Abd-Elsalam et al., 2020; Furtado
et al., 2020). Cavalcanti et al. (2020) reported 15-day mortality of
1.7% with HCQ plus azithromycin (HCQ 400 mg twice daily plus
azithromycin 500 mg once daily for 7 days), 3.1% with HCQ alone
(HCQ 400 mg twice daily for 7 days), and 2.9% with control
treatment. Horby et al. (2020) reported that patients randomized
to receive HCQ (n = 1561) had 28-day all-cause mortality of 26.8%,
while patients who randomized to receive usual care (n = 3155)
had 28-day all-cause mortality of 25.0%. In the trial by Abd-Elsalam
et al. (2020), death at 28 days occurred in 6.1% of patients in the
HCQ group (400 mg twice daily on day 1, followed by 200 mg twice
daily for another 14 days; n = 97) and 5.1% of patients in the control
group (n = 97). Furtado et al. (2020) randomized patients to receive
either HCQ (400 mg twice daily for 10 days; n = 183) or HCQ plus
azithromycin (HCQ 400 mg twice daily plus azithromycin 500 mg
once daily for 10 days; n = 214), and reported that death at 29 days
occurred in 40% of patients in the HCQ group and 42% of patients in
the HCQ plus azithromycin group.
The other outcome measure in HCQ trials was radiological lung
clearance, where Chen et al. (2020b) used a dosing regimen of 400
mg daily and reported an improvement in radiological results on
day 6 in 80.6% of patients in the HCQ arm (n = 31) versus 54.8% of
patients in the control arm (n = 31).
Boulware et al. (2020) reported the incidence of either
laboratory-confirmed COVID-19 or illness compatible with
COVID-19 within 14 days of administration of either HCQ (800
mg once, followed by 600 mg in 6–8 h, then 600 mg daily for an
additional 4 days) or placebo for patients who had been exposed to
individuals with confirmed COVID-19, and reported a lower
incidence of 11.8% in the HCQ arm (n = 414) compared with
14.3% in the placebo arm (n = 407). Mitjà et al., 2020 compared the
incidence of laboratory-confirmed symptomatic COVID-19 within
14 days of administration of either HCQ (800 mg on day 1, followed
by 400 mg once daily for 6 days; n = 1,116) or treatment with usual
care (n = 1198) for healthy contacts of COVID-19 index patients, and
observed that the incidence was lower in the HCQ arm (5.7%) than
in the usual care arm (6.2%).
For CQ trials, Huang et al. (2020b) compared CQ in a regimen of
500 mg orally twice daily for 10 days (n = 10) with lopinavir/
ritonavir in a regimen of 400 mg/100 mg for 10 days (n = 12), and
observed that all patients in the CQ arm achieved virological
clearance on day 14, while 11 of 12 patients in the lopinavir/
ritonavir arm achieved virological clearance on day 14. In terms of
lung clearance rate based on computed tomography findings, 60%
of patients in the CQ group achieved radiological lung clearance by
day 9, compared with 25% in the lopinavir/ritonavir group. Borba
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AIDS, acquired immunodeficiency syndrome: AZT, azithromycin; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CQ, chloroquine; HCQ, hydroxychloroquine; HIV, human immunodeficiency
virus; ICU, intensive care unit; NR, not reported; RCT, randomized controlled trial; SD, standard deviation; SOC: standard of care.






























116 F. Mazhar, M.A. Hadi, C.S. Kow et al. / International Journal of Infectious Diseases 101 (2020) 107–120and low (450 mg twice daily on day 1 and once daily for 4 days; n =
40) doses of CQ, and reported higher mortality (17.5%) with the
high-dose regimen than with the low-dose regimen (9.7%).
Reporting of harms
Tang et al. (2020) in their HCQ trial found a higher rate of any
AEs among HCQ recipients (30.0%, n = 21/70) compared with
patients who received standard of care treatment (8.8%, n = 7/80).
Similarly, Boulware et al. (2020) reported a higher rate of any AEs
in HCQ recipients (40.1%, n = 140/414) relative to placebo recipients
(16.8%, n = 59/407). In both trials, the most common AE among the
HCQ recipients was diarrhoea (10.0%, n = 7/70, in the trial by Tang
et al. (2020) and 19.6%, n = 81/414, in the trial by Boulware et al.
(2020)). This was also reported in a larger trial by Esper et al.
(2020), who also reported diarrhoea (16.5%, n = 68/412) as the most
common AE among 412 patients who received HCQ.
In both trials by Mitjà et al., 2020a, 2020, there was also a higher
rate of any AEs in the HCQ arm compared with the control/placebo
arm (72.0%, n = 121/169, versus 8.7%, n = 16/184, in the trial by Mitjà
et al., 2020a and 51.6%, n = 671/1,197, versus 5.9%, n = 77/1300, in
the trial by Mitjà et al., 2020b). The most frequent AEs reported
among participants given HCQ in both trials by Mitjà et al., 2020a,
2020 were related to the gastrointestinal system (diarrhoea,
nausea, and abdominal pain) without individual presentation of
the AEs. Similarly, Skipper et al. (2020) reported more frequent
occurrences of any AEs in the HCQ group (43.4%, n = 92/212, versus
21.8%, n = 46/211), with the most frequent AEs reported being upset
stomach and nausea (31.1%, n = 66/212).
Although more AEs were also reported in the trial by Cavalcanti
et al. (2020) in patients who received HCQ plus azithromycin (n =
94/239, 39.3%) or HCQ alone (n = 67/199, 33.7%) than in those who
received azithromycin alone (n = 9/50, 18.0%) or neither of the trial
drugs (n = 40/177, 22.6%), a corrected QT interval greater than 480
ms within 7 days was the most frequent AE observed in patients
who received HCQ (14.7%, n = 17/116, in the HCQ plus azithromycin
group and 14.6%, n = 13/89, in the HCQ-alone group). Chen et al.
(2020b) reported two patients (3.2%) with mild adverse reactions
in the HCQ group (n = 31), where one patient developed a rash and
one patient experienced a headache, while no patients experi-
enced an AE in the control group.
Furtado et al. (2020) did not compare the proportion of patients
with any AEs between HCQ recipients and HCQ plus azithromycin
recipients, although they reported a higher proportion of serious
AEs among HCQ plus azithromycin recipients (42%, n = 102/241)
relative to HCQ recipients (38%, n = 75/198). Similarly, Chen et al.
(2020c) did not compare the proportion of patients with AEs
between the two study arms, although they reported headache as
the most frequent grade 1 and grade 2 HCQ-related AEs.
Huang et al. (2020b) in their CQ trial observed that almost all of
the patients (n = 9/10) experienced CQ-related AEs, with the most
common AEs being vomiting (n = 5) and diarrhoea (n = 5). Borba
et al. (2020), who compared a high-dose regimen and a low-dose
regimen of CQ, reported that a higher proportion of patients (in the
safety population) who received high-dose CQ (18.9%, n = 7/37)
experienced QT prolongation compared with patients who
received low-dose CQ (11.1%, n = 4/36).
Among the trials (Borba et al., 2020; Boulware et al., 2020;
Cavalcanti et al., 2020; C. Chen et al., 2020; Z. Chen et al., 2020;
Furtado et al., 2020; Huang et al., 2020; Mitjà et al., 2020a, 2020b;
Skipper et al., 2020; Tang et al., 2020; Esper et al., 2020) which
presented harm data (n = 12), all trials presented harm data in both
text and table form except the trial by Chen et al. (2020c), which
presented harm data in text form only. Nevertheless, only four
(Boulware et al., 2020; Cavalcanti et al., 2020; Mitjà et al., 2020;
Skipper et al., 2020) of the 12 trials described the scale or anycriteria used to measure the severity of AEs. In all but four trials
(Boulware et al., 2020; Furtado et al., 2020; Mitjà et al., 2020;
Skipper et al., 2020), safety data were presented as frequencies
only, without a statistical comparison of the occurrence of the AE
between the investigational arm and the control arm. All but the
two trials by Esper et al. (2020) and Skipper et al. (2020) attributed
AEs to HCQ. Nine trials (Cavalcanti et al., 2020; C. Chen et al., 2020;
Z. Chen et al., 2020; Furtado et al., 2020; Huang et al., 2020; Mitjà
et al., 2020a, 2020b; Skipper et al., 2020; Tang et al., 2020) reported
both frequent and serious AEs, while the other three trials (Esper
et al., 2020; Borba et al., 2020; Boulware et al., 2020) reported only
AEs selected by the investigators.
Out of a maximum score of 19, the median THRS was 6.5
(interquartile range 5). Among the total of 19 CONSORT items, all
but five trials (Borba et al., 2020; Cavalcanti et al., 2020; Furtado
et al., 2020; Mitjà et al., 2020; Skipper et al., 2020) reported less
than 50% of the items (THRS range 1–9). Only the two trials by
Borba et al. (2020) and Cavalcanti et al. (2020) reported more than
60% of the items (THRS 13).
Adherence to CONSORT recommendations
The number and percentages of the randomized controlled
trials fulfilling each of the CONSORT harm recommendations are
presented in Table 2. Scoring for each recommendation can be
found in Table S1. Nine trials (Borba et al., 2020; Boulware et al.,
2020; Cavalcanti et al., 2020; Chen et al., 2020; Furtado et al., 2020;
Mitjà et al., 2020a, 2020b; Skipper et al., 2020; Tang et al., 2020)
mentioned AEs in the title or abstract (CONSORT recommendation
1). However, only five trials (Esper et al., 2020; Borba et al., 2020;
Cavalcanti et al., 2020; Abd-Elsalam et al., 2020; Furtado et al.,
2020) provided information on AEs in the introductory section
(CONSORT recommendation 2). Although only five trials (Boulware
et al., 2020; Cavalcanti et al., 2020; Horby et al., 2020; Mitjà et al.,
2020; Skipper et al., 2020) used a validated scale to measure the
severity of AEs, half of the trials (n = 8) (Borba et al., 2020; Boulware
et al., 2020; Cavalcanti et al., 2020; Chen et al., 2020; Furtado et al.,
2020; Mitjà et al., 2020; Tang et al., 2020; Esper et al., 2020)
defined the AEs (CONSORT recommendations 3) in their report.
Only seven trials (Borba et al., 2020; Boulware et al., 2020;
Cavalcanti et al., 2020; Chen et al., 2020; Mitjà et al., 2020a, 2020b;
Skipper et al., 2020) described how AE-related data were collected
(CONSORT recommendation 4 (4a)), but more than half of the trials
(n = 9) (Borba et al., 2020; Boulware et al., 2020; Cavalcanti et al.,
2020; J. Chen et al., 2020; Z. Chen et al., 2020; Mitjà et al., 2020a,
2020b; Skipper et al., 2020; Esper et al., 2020) described when AE
data were collected (CONSORT recommendation 4 (4b)). Only two
trials (Borba et al., 2020; Cavalcanti et al., 2020) described methods
of presenting and/or analysing AEs (CONSORT recommendation 5).
Fewer than half of the trials (n = 7) (Borba et al., 2020; Boulware
et al., 2020; Chen et al., 2020; Huang et al., 2020; Mitjà et al., 2020;
Skipper et al., 2020; Tang et al., 2020) described the number of
withdrawals due to AEs in each arm (CONSORT recommendation 6
(6a)). More than half of the trials (n = 10) (Borba et al., 2020;
Boulware et al., 2020; Cavalcanti et al., 2020; C. Chen et al., 2020; J.
Chen et al., 2020; Furtado et al., 2020; Huang et al., 2020; Mitjà
et al., 2020a, 2020b; Skipper et al., 2020) provided denominators
for AEs (CONSORT recommendation 7 (7a)). Most of the trials
presented results for each arm separately (n = 13) (Borba et al.,
2020; Boulware et al., 2020; Cavalcanti et al., 2020; C. Chen et al.,
2020; J. Chen et al., 2020; Z. Chen et al., 2020; Furtado et al., 2020;
Horby et al., 2020; Mitjà et al., 2020a, 2020b; Skipper et al., 2020;
Tang et al., 2020; Esper et al., 2020) and presented a balanced
discussion on both the safety and the efficacy of the drug (n = 11)
(Abd-Elsalam et al., 2020; Borba et al., 2020; Cavalcanti et al., 2020;
Chen et al., 2020; Furtado et al., 2020; Horby et al., 2020; Huang
Table 2
Items adequately reported against the quality of reporting criteria (Consolidated Standards of Reporting Trials (CONSORT) Extension for Harm).
Recommendations of 2004 CONSORT harm extension Quality of reporting criteria Number of
trials
1. If the study collected data on harms and benefits, the title of the abstract should state so Adverse events mentioned in the title 0 (0%)
Adverse events mentioned in the abstract 9 (56%)
2. If the trial addresses both harms and benefits, the introduction should state so Information on adverse events mentioned in the introduction 5 (31%)
3. List addressed adverse events with definitions for each (with attention, when relevant, to
grading, expected versus unexpected events, reference to standardized and validated
definitions, and description of new definitions)
3a. If article mentioned the use of a validated instrument to
report adverse event severity
5 (31%)
3b. If article mentioned definition of adverse event 8 (50%)
4. Clarify how harm-related information was collected (mode of data collection, timing,
attribution methods, intensity of ascertainment, and harm-related monitoring and
stopping rules, if pertinent)
4a. Description of how harm data were collected (e.g. diaries,
phone interviews, face-to-face interviews)
7 (44%)
4b. Description of when adverse event data were collected 9 (56%)
4c. Whether or not adverse events were attributed to trial drug
(e.g. how adverse events were attributed to drugs)
2 (13%)
5. Describe plans for presenting and analysing information on harms (including coding,
handling of recurrent events, specification of timing issues, handling of continuous
measures, and any statistical analyses)
5. Description of methods for presenting and/or analysing
adverse events
2 (13%)
6. Describe for each arm the participant withdrawals that are due to harms and the
experience with the allocated treatment
6a. If the article reported number of withdraws caused by adverse
events in each arm
7 (44%)
6b. Description of adverse events leading to withdrawals 5(31%)
6c. Description of adverse events leading to death 2 (13%)
7. Provide the denominators for analyses on harms 7a. If the article provided denominators for adverse events 10 (63%)
7b. If the article provided definitions used for analysis set
(intention to treat, per protocol, safety data available, unclear)
3 (19%)
8. Present the absolute risk of each adverse event (specifying type, grade, and seriousness
per arm), and present appropriate metrics for recurrent events, continuous variables, and
scale variables, whenever pertinent
8a. Results presented separately for each arm 13 (81%)
8b. Separate reporting of severe adverse events s (grade >2 or
serious adverse events)
11 (69%)
8c. Provided both number of adverse events and number of
patients with adverse events
2 (13%)
9. Describe any subgroup analyses and exploratory analyses for harms – 2 (13%)
10. Provide a balanced discussion of benefits and harms with emphasis on study
limitations, generalizability, and other sources of information on harms
10a. If the discussion was balanced with regard to efficacy and
adverse events
9 (56%)
10b. Limitations of the study specifically in relation to adverse
events discussed
2 (13%)
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et al., 2020) (CONSORT recommendations 8 (8a) and 10 (10a)). The
trials by Esper et al. 2020 and Cavalcanti et al. (2020) were the only
trials that described subgroup analyses and exploratory analyses
for harms (CONSORT recommendation 9).
Risk of bias
The risk of bias analysis using the RoB 2 and ROBINS-I
frameworks for the 16 trials included in this review is summarized
in Figure 2. Surprisingly, none of the 16 clinical trials scored an
overall ‘low risk’, four trials scored a high (Tang et al., 2020;
Boulware et al., 2020), critical (Gautret et al., 2020), or serious
(Esper et al., 2020) risk, and the remaining trials (Abd-Elsalam
et al., 2020; Borba et al., 2020; Cavalcanti et al., 2020; C. Chen et al.,
2020; J. Chen et al., 2020; Z. Chen et al., 2020; Furtado et al., 2020;
Horby et al., 2020; Huang et al., 2020; Mitjà et al., 2020a, 2020b;
Skipper et al., 2020) were classified into a moderate risk.
Among the 14 randomized controlled trials (Abd-Elsalam et al.,
2020; Borba et al., 2020; Boulware et al., 2020; Cavalcanti et al.,
2020; C. Chen et al., 2020; J. Chen et al., 2020; Z. Chen et al., 2020;
Furtado et al., 2020; Horby et al., 2020; Huang et al., 2020; Mitjà
et al., 2020a, 2020b; Skipper et al., 2020; Tang et al., 2020) included
in this review which had their risks of bias assessed with RoB 2, all
of the trials had at least some concerns of risk of bias in at least one
of the bias domains in RoB 2. The most significant risk of bias across
all 14 randomized controlled trials was bias in the measurement of
the outcome, in which 11 of the trials (Abd-Elsalam et al., 2020;
Borba et al., 2020; Boulware et al., 2020; Cavalcanti et al., 2020; C.
Chen et al., 2020; Z. Chen et al., 2020; Furtado et al., 2020; Horby
et al., 2020; Mitjà et al., 2020a, 2020b; Tang et al., 2020) had at least
some concerns on this domain of bias. Such concerns were due to
the possibility that assessments of outcomes, either efficacy
outcomes or outcomes of occurrence of AEs, would be affected byknowledge of the intervention assignment by the outcome
assessors owing to the open-label study design. The trial by
Boulware et al. (2020) had a particularly high risk of bias in the
measurement of the outcome because 24% of those randomized to
receive the study treatment were excluded in the analysis on the
outcome of occurrence of AEs. Although similar proportions of
participants were excluded from analysis in the two groups on the
outcome of the occurrence of AEs, the reasons for exclusion differ
between the two arms and are likely to be related to the outcome.
Also, the trial by Boulware et al. (2020) had some concerns of bias
due to missing outcome data since there were critical differences
between interventions in the proportion of participants with
missing data (4.1% of patients in HCQ-treated group, whereas 2.0%
of patients in the placebo group discontinued treatment).
Another significant risk of bias across the included randomized
trials was bias due to deviations from the intended intervention, in
which nine of the trials (Abd-Elsalam et al., 2020; Cavalcanti et al.,
2020; Chen et al., 2020; Furtado et al., 2020; Horby et al., 2020;
Huang et al., 2020; Mitjà et al., 2020a, 2020b; Skipper et al., 2020)
had some concerns on this domain of bias. These trials provided no
information on co-interventions of interest such as the use of
systemic corticosteroids and antivirals among participants, and
thus signalled some concerns regrading the existence of bias due to
the possibility of unequal use of co-interventions of interest
between the study groups.
The trial by Tang et al. (2020) had an overall high risk of bias,
with a particularly high risk of bias arising from the randomization
process; it was an open-label study and the authors did not assess
baseline differences between intervention groups. Also, a high risk
of bias was noted in the trial by Tang et al. (2020) in the selection of
the reported results as there were unplanned analyses of the
changes in C-reactive protein values and blood lymphocyte count,
and there were unplanned post hoc subgroup analyses. The trial by
Chen et al. (2020b) exhibited some concerns regarding the risk of
Figure 2. Summary of risk of bias: (a) RoB 2 for randomized trials; (b) Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) tool for non-randomized trials.
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Horby et al. (2020) and Abd-Elsalam et al. (2020) had some
concerns regarding the risk of bias in all the domains assessed
except the domain of bias arising from the randomization process
in the former and the domain of bias due to missing outcome data
in the latter. The trial by Chen et al. (2020a) was noted to have the
least risk of bias, with some concerns regarding the randomization
process since no information was provided about the concealment
of the allocation sequence, while all the other domains had a low
risk of bias.
The trial by Borba et al. (2020) had some concerns regarding the
risk of bias in the selection of the reported results because of the
early interruption of the high-dose treatment, the unmasking of
treatment allocation in some participants, and missing data on
radiological findings. BoBbBoth the trials by Mitjà et al., 2020 and
Skipper et al. (2020)had some concerns regarding the risk of bias
due to deviations from the intended intervention. The trial by Mitjà
et al., 2020 also had some concerns regrading the risk of bias in the
selection of the reported results because of the unavailability of the
study protocol and statistical analysis plan. The trial by Skipper
et al. (2020) also had some concerns regarding the risk of bias
arising from the randomization process because 20% of the
participants assigned to the intervention and control arms were
also randomized in a separate trial. Moreover, with nearly 5% of
participants with missing data for death as the outcome and with
more than 10% of participants with missing data for the primary
outcome in the trial by Skipper et al. (2020), there appear to be
some concerns regarding the risk of bias due to missing outcome
data. Although the trial by Chen et al. (2020c) had a low risk of bias
due to deviations from the intended intervention, there were some
concerns regarding the risk of bias arising from the randomization
process because of differences in the proportion of participants
with mild disease severity and moderate disease severity between
the two study arms at the baseline and some concerns regarding
the risk of bias in the selection of the reported results because of
unavailability of the study protocol and statistical analysis plan.
The risk of bias for non-randomized controlled trials (Gautret
et al., 2020; Esper et al., 2020) was assessed with the ROBIN-I tool.
Across the seven domains of the risk of bias in the ROBIN-I tool, the
trial by Gautret et al. (2020) had at least a moderate risk of bias inall domains except bias in the measurement of outcomes (low
risk). In particular, the trial by Gautret et al. (2020) had a critical
risk of bias due to missing data, in which there were critical
differences between the two intervention arms in the proportion
of participants with missing data (30% of HCQ-treated patients
were lost to follow-up, while no patients (0%) were lost to follow-
up in the control group), and a serious risk of bias due to
confounding because of the baseline differences in participants’
characteristics between the treatment arm and the control arm.
Also, the trial had a serious risk of bias due to deviations from the
intended interventions since the use of important co-intervention
(azithromycin) was not balanced across the intervention groups.
For the trial by Esper et al. (2020), a serious risk of bias in the
classification of interventions and a serious risk of bias due to
missing data were observed. The remaining domains for the trial
by Esper et al. (2020) had either low or moderate risk of bias.
Discussion
This systematic review was aimed to critically assess and
summarize the quality of published clinical trials evaluating the
effectiveness of CQ or HCQ in the treatment of COVID-19. Overall,
the 16 trials (Abd-Elsalam et al., 2020; Borba et al., 2020; Boulware
et al., 2020; Cavalcanti et al., 2020; C. Chen et al., 2020; J. Chen
et al., 2020; Z. Chen et al., 2020; Furtado et al., 2020; Gautret et al.,
2020; Horby et al., 2020; Huang et al., 2020; Mitjà et al., 2020a,
2020b; Skipper et al., 2020; Tang et al., 2020; Esper et al., 2020)
included in our review recruited 10,873 participants (5036 patients
in the HCQ/CQ group and 5837 patients in the comparator group).
Potentially a meta-analysis of these trials would have definitively
answered the effectiveness and safety questions regarding CQ or
HCQ in the treatment of COVID-19, but given the methodological
inadequacies in these trials, a meta-analysis is likely to produce
misleading outcomes.
Since the publicity of HCQ/CQ in the press as a potential cure for
COVID-19 on the basis of promising preliminary clinical experi-
ences (Liu et al., 2020) and in vitro investigations (Gao et al., 2020),
several trials were designed across the world to testify the
effectiveness and safety of these antimalarial drugs for the
treatment of COVID-19. However, we found that most of these
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statistical power and significance. On critical review of the trial
design and reporting, we found that the findings from these trials
were far from conclusive, in which inferences were contradictory
and findings were significantly confounded by covariates such as
comorbidities and/or use of co-interventions, along with lack of
adjustment for disease severity at the baseline. Indeed, some trials
provided no information on the baseline severity for the patients
recruited. Moreover, all trials were associated with moderate to
high risk of bias; the examples included risks of bias arising from
the randomization process, potential deviation from intended
interventions, outcome measurements, selective reporting, con-
founding, participant selection, and/or classification of interven-
tions. Also, none of the trials included in this review met the
CONSORT criteria in full for reporting harms in the trials, with few
trials presenting no harm data. Although HCQ/CQ has a history of
safe use, AEs such as toxic retinopathy and corrected QT
prolongation especially may have a fatal consequence and,
therefore, inadequate reporting on AEs in these trials can be
misleading and pose serious risks to public safety, particularly
during more widespread use during the COVID-19 pandemic. This
is not surprising given that amid the current pandemic, researchers
may place stronger emphasis on the benefits than the risks in an
attempt to save lives.
It is, however, acknowledged that there are genuine method-
ological challenges in designing studies for COVID-19 pandemic
crises and there is a great sense of urgency for the containment of
the COVID-19 pandemic. A recent editorial by Knottnerus and
Tugwell (2020) critically summarized these issues. However, the
quality of trial design and reporting is imperative for the adoption
of trial findings in clinical practice as poorly designed or poorly
reported trials can only lead to contradictory findings and
confusion among front-line clinicians in their decision-making
in the management of patients with COVID-19. Clinicians are
eagerly looking for definitive answers as to what works and what
does not, and they may not have sufficient time amid the COVID-
19 emergency to critically appraise every single trial. Complete
and accurate reporting is, therefore, invaluable to inform policy-
makers and guide clinical decisions. Furthermore, the responsi-
bility to ensure a greater balance between reporting of both
benefits and harms lies with the authors and the journals
publishing those trials. Although we acknowledge the limited
availability of space in journals often leads to selective reporting
of outcomes, it should not be an excuse since this can be easily
overcome by the reporting of supplementary data. We hope that
this review will encourage clinical researchers to better design,
conduct, and report trials to uphold the principles of evidence-
based medicine even amid a global health emergency such as
COVID-19.
Strengths and limitations
The strengths of our review lie in the comprehensive literature
search. We used multiple databases, such as PubMed and EMBASE,
a clinical trial registry, and a COVID-19 specific database
(Dimensions) to search for relevant clinical trials. Furthermore,
we used standardized quality reporting tools and methods used in
the synthesis of evidence, in which for research synthesis we
followed standard PRISMA guidelines in searching for, selection of,
inclusion of, and exclusion of studies, as well as for data extraction.
We evaluated the harm reporting and risk of bias in the included
trials using standardized CONSORT harm recommendations and
the RoB 2 and ROBINS-I tools, respectively.
Although we used all the possible terms, free-text terms, and
the MeSH terms to search for relevant HCQ/CQ clinical trials, the
sensitivity of our strategy is still unknown. In addition, as withmost studies examining the design and reporting methods, it is
challenging particularly when the reporting of these aspects is
incomplete. An example of this is the reporting of baseline disease
activity in the HCQ/CQ trials, where it can be difficult to determine
the methodology used as it was often not defined.
Implications of this research
There are implications of this work in designing and conducting
randomized controlled trials for the treatment of COVID-19. This
review suggests that basic requirements for designing and
conducting randomized controlled trials should never be com-
promised, and a standardized protocol must be used and followed.
It is also important that confounders should always be identified
and adjusted. To uphold public trust in medical practice amid the
COVID-19 pandemic, randomized controlled trials should be
designed and reported more exhaustively, particularly when the
effects of the specific treatment that could be potentially life-
saving are being reported. The authors should always report all AEs
experienced by the patients during a trial with optimal quality
standards (CONSORT harm recommendations), where all AEs
(instead of a mere selection) are explicitly described and provide
details for patients who dropped out because of AEs. Definitions of
baseline disease activity should always be provided (and
appropriately adjusted if there are differences) to determine if a
particular treatment is effective in the mild, moderate, severe, or
critical stage of the disease.
Conclusion
Given the quality of evidence available, it is not possible to draw
a meaningful conclusion on the effectiveness and the safety of CQ
or HCQ for the treatment of patients with COVID-19. The quality of
evidence should be carefully considered in the making of clinical
and policy decisions, particularly during a pandemic. The
importance of designing and reporting trials properly cannot be
overemphasized for the synthesis of clinical evidence, and its
dismissal in its entirety or partially amid pandemic crises could not
only lead to a waste of invaluable health care resources but may
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